ValuEngine Upgrades Dr. Reddy’s Laboratories (NYSE:RDY) to “Hold”

Dr. Reddy’s Laboratories (NYSE:RDY) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Monday, April 2nd.

Separately, Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $30.51.

How to Become a New Pot Stock Millionaire

NYSE RDY opened at $32.68 on Monday. Dr. Reddy’s Laboratories has a twelve month low of $29.83 and a twelve month high of $42.97. The stock has a market capitalization of $5,454.10, a PE ratio of 32.24 and a beta of 0.28. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 1.13.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 25th. The company reported $0.41 EPS for the quarter. The company had revenue of $596.00 million during the quarter. Dr. Reddy’s Laboratories had a return on equity of 8.79% and a net margin of 6.95%. equities research analysts predict that Dr. Reddy’s Laboratories will post 1.07 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its position in shares of Dr. Reddy’s Laboratories by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 581,938 shares of the company’s stock worth $20,769,000 after purchasing an additional 8,200 shares in the last quarter. Mondrian Investment Partners LTD boosted its position in shares of Dr. Reddy’s Laboratories by 32,335.1% in the 4th quarter. Mondrian Investment Partners LTD now owns 356,786 shares of the company’s stock worth $13,401,000 after purchasing an additional 355,686 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Dr. Reddy’s Laboratories by 22.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,276 shares of the company’s stock worth $10,678,000 after acquiring an additional 54,214 shares during the period. Dalton Investments LLC lifted its position in Dr. Reddy’s Laboratories by 10.6% during the 4th quarter. Dalton Investments LLC now owns 229,000 shares of the company’s stock worth $8,601,000 after acquiring an additional 22,000 shares during the period. Finally, Hexavest Inc. lifted its position in Dr. Reddy’s Laboratories by 153.4% during the 4th quarter. Hexavest Inc. now owns 187,579 shares of the company’s stock worth $7,045,000 after acquiring an additional 113,547 shares during the period. 13.14% of the stock is owned by hedge funds and other institutional investors.

WARNING: “ValuEngine Upgrades Dr. Reddy’s Laboratories (NYSE:RDY) to “Hold”” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/12/dr-reddys-laboratories-rdy-lifted-to-hold-at-valuengine.html.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply